Design, synthesis and biological evaluation of novel N-(methyl-d3) pyridazine-3-carboxamide derivatives as TYK2 inhibitors.

[1]  Sheridan M. Hoy.  Deucravacitinib: First Approval , 2022, Drugs.

[2]  Fei Liu,et al.  Novel TYK2 Inhibitors with an N-(Methyl-d 3)pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases. , 2022, ACS medicinal chemistry letters.

[3]  Stanley B. Cohen,et al.  Oral surveillance and JAK inhibitor safety: the theory of relativity , 2022, Nature Reviews Rheumatology.

[4]  Xiaoying Hu,et al.  The JAK/STAT signaling pathway: from bench to clinic , 2021, Signal Transduction and Targeted Therapy.

[5]  T. Matsuda,et al.  Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory Diseases. , 2021, Biological & pharmaceutical bulletin.

[6]  Subhashish Banerjee,et al.  Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors , 2021, Dermatology and Therapy.

[7]  C. Harrison,et al.  Current and future status of JAK inhibitors , 2021, The Lancet.

[8]  T. Torres,et al.  Baricitinib for the treatment of atopic dermatitis , 2021, The Journal of dermatological treatment.

[9]  P. Leszczyński,et al.  TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases. , 2021, Immunotherapy.

[10]  Baohui Song,et al.  Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease , 2021, Inflammation Research.

[11]  James Lin,et al.  Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2. , 2020, Journal of medicinal chemistry.

[12]  D. Mccole,et al.  The JAK-Inhibitor Tofacitinib Rescues Human Intestinal Epithelial Cells and Colonoids from Cytokine-Induced Barrier Dysfunction. , 2019, Inflammatory bowel diseases.

[13]  S. Spergel,et al.  Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. , 2019, Journal of medicinal chemistry.

[14]  S. Spergel,et al.  Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2). , 2019, Journal of medicinal chemistry.

[15]  K. Yamaoka.  Tofacitinib for the treatment of rheumatoid arthritis: an update , 2019, Expert review of clinical immunology.

[16]  James Lin,et al.  Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors. , 2019, ACS medicinal chemistry letters.

[17]  M. González-Gay,et al.  The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib. , 2019, Clinical and experimental rheumatology.

[18]  H. Hoffman,et al.  JAK inhibitors in autoinflammation. , 2018, The Journal of clinical investigation.

[19]  J. Tokarski,et al.  Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling. , 2017, MedChemComm.

[20]  Yuka Kanno,et al.  Mechanisms and consequences of Jak–STAT signaling in the immune system , 2017, Nature Immunology.

[21]  R. Roskoski.  Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. , 2016, Pharmacological research.

[22]  Stephen R. Johnson,et al.  Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain* , 2015, The Journal of Biological Chemistry.

[23]  F. Powrie,et al.  Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. , 2006, Immunity.